Like her predecessor, Sally Choe likely will have to spend some time getting to know industry and other stakeholders once she becomes director of the US FDA's Office of Generic Drugs.
Choe, whom the agency announced Feb. 12 will take over for Kathleen Uhl in March, appears to be a relative unknown to the generic industry